1. Pink Sheet
  2. >>Vaccines

Breaking: US FDA Cancels Upcoming Adcomm Discussing 2025-2026 Flu Vaccine

 
• By Sarah Karlin-Smith and Derrick Gingery

The Vaccines and Related Biological Products Advisory Committee meeting next month was scheduled to select strains for the 2025-2026 flu vaccine. The cancellation could mean delays in vaccine availability.

Pharmacy with sign saying flu shot.
The FDA canceled a planned VRBPAC meeting to discuss flu vaccine strain selection for next season. (Shutterstock)
Key Takeaways
  • The FDA cancelled the 13 March VRBPAC meeting intended to select strains for the 2025-2026 flu vaccine for the Northern Hemisphere.
  • Because companies need about six months to manufacture the vaccine in time for the start of flu season, the delay could impact availability.
  • The VRBPAC meeting cancellation follows the CDC postponing the 26-28 February Advisory Committee on Immunization Practices meeting.

The US Food and Drug Administration has cancelled the 13 March meeting of its Vaccines and Related Biological Products Advisory Committee, which was

Committee member Paul Offit, a pediatrics professor in the Division of Infectious Diseases at the Children’s Hospital of Philadelphia, confirmed to the Pink Sheet that the agency emailed 26 February to notify him the meeting had been cancelled

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Product Reviews

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.

Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman

The US FDA seeks advice on the clinical meaningfulness of the endpoints of J&J’s AQUILA trial in smoldering multiple myeloma, highlighting the pitfalls of being the first candidate for the precancerous condition.

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.